Taysha Gene Therapies, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €401.01M +278.8% €107.39M -250.7% 26.8% +0.94 pp N/A N/A
    (estimated) €105.87M +68.4% -€71.25M -7.0% -67.3% +0.55 pp N/A N/A
    (estimated) €62.86M +1,409.7% -€76.62M -31.3% -121.9% +26 pp N/A N/A
    (estimated) €4.16M -30.1% -€111.58M +23.6% -2,680.0% -12 pp -€82.75M +7.6% -1,987.6% -7.0 pp
    (estimated) €5.96M -16.7% -€90.27M +17.8% -1,515.1% -4.4 pp -€76.88M +10.8% -1,290.5% -3.2 pp
    €7.15M -46.1% -€76.66M -20.0% -1,071.6% -3.5 pp -€69.41M +23.2% -970.3% -5.5 pp
    €13.26M +517.5% -€95.77M -34.2% -722.1% +61 pp -€56.36M +3.4% -424.9% +21 pp
    €2.15M +∞% -€145.58M -3.4% -6,777.8% -68 pp -€54.53M -33.5% -2,538.8% -25 pp
    €0.00 +NaN% -€150.62M +308.0% N/A -€81.97M +341.1% N/A
    €0.00 +NaN% -€36.91M +3,756.5% N/A -€18.58M -16,134.8% N/A
    €0.00 -€957.16K N/A €115.89K N/A

    Notifications